Gettinger S, et al. Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC. Abstract OA14.04. WCLC 7-10 sept. 2019, Barcelona, Spanje.
Adjuvant ipilimumab bij stadium III-melanoom
jan 2017 | Dermato-oncologie, Immuuntherapie